An FDA advisory panel, more than a third of whose members have financial ties to the peptide industry, opened a two-day review of seven injectable substances that lack meaningful human safety data, a process one FDA-law attorney says will likely end the way Health Secretary Robert F. Kennedy Jr. wants. The Food and Drug Administration […] The post FDA panel stacked with peptide industry insiders reviews unproven injections backed by RFK Jr. appeared first on American Almanac .
An FDA advisory panel, more than a third of whose members have financial ties to the peptide industry, opened a two-day review of seven injectable substances that lack meaningful human safety data, a process one FDA-law attorney says will likely end the way Health Secretary Robert F. Kennedy Jr. wants. The Food and Drug Administration convened twenty outside advisers in Washington this week to vote on whether seven peptides should be added to a federal list that would let compounding pharmacies legally mix and sell them by prescription. Kennedy has described himself as a "big fan" of the substances and has vowed to roll back restrictions imposed during the Biden administration. His fingerprints are on the proceeding: at least seven of the…Open
Next week, a Food and Drug Administration (FDA) advisory committee will decide whether seven still-unapproved peptides should be added to the list of substances America's compounding pharmacies can legally use.
Next week, a Food and Drug Administration (FDA) advisory committee will decide whether seven still-unapproved peptides should be added to the list of substances America’s compounding pharmacies can legally use. The FDA’s own career scientists have already reviewed the evidence and recommended against it . The committee weighing that recommendation, however, is stacked with people who make money selling these peptides. The broader gray market this vote would help legitimize already includes Chinese chemical manufacturers who, until recently, were supplying the precursor chemicals behind America’s fentanyl epidemic. CHINA’S EXPLOITATION. Fentanyl remains the leading cause of death for Americans aged 18 to 45, involved in roughly…Open
Marketed for longevity and wellness benefits, the unproven therapies are sold through a grey market online. Compounding pharmacies say they should be able to make them legally to meet demand.
Documents reviewing the research on peptides note lack of good evidence of efficacy or safety. Yet an FDA panel will consider easing access to them later this month.
Health Secretary Robert F. Kennedy Jr.'s new push to loosen federal restrictions on peptides could be a bonanza for telehealth companies, compounding pharmacies and longevity clinics looking for the next big wellness trend. Why it matters: The heavily touted but loosely regulated proteins could fuel the kind of boom we've seen with weight-loss drugs — even though there's little evidence they work in humans. State of play: The self-administered injections have become the rage among fitness enthusiasts, celebrities and consumers seeking to heal injuries, reduce inflammation and find anti-aging benefits. - The interest has been juiced by social media influencers and podcasters like Joe Rogan, who hosted a segment in February during which…
A month ago, Health Secretary Kennedy said his agency would soon give compounding pharmacies the greenlight to make the products, which have exploded in popularity despite a lack of data.
The peptides, which are increasingly marketed as providing longevity and health benefits, were removed in 2023 from the agency’s list of products that compounding pharmacies can sell.
The latest wellness craze involves injecting these molecules for athletic performance, longevity and more. Scientists say the research isn't keeping pace with the health claims.